608 related articles for article (PubMed ID: 22082161)
1. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
2. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
3. Safety of omalizumab in asthma.
Tan RA; Corren J
Expert Opin Drug Saf; 2011 May; 10(3):463-71. PubMed ID: 21401438
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
5. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
6. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
9. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
10. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
Chen H; Eisner MD; Haselkorn T; Trzaskoma B
Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
[TBL] [Abstract][Full Text] [Related]
11. Eligibility for treatment with omalizumab in Italy and Germany.
Buhl R; Marco AG; Cohen D; Canonica GW
Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
[TBL] [Abstract][Full Text] [Related]
12. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
13. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in asthma: an update on recent developments.
Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
16. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
Leuenberger P; Sauty A; Rochat T
Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
[TBL] [Abstract][Full Text] [Related]
17. Targeting IgE in asthma.
Kuhl K; Hanania NA
Curr Opin Pulm Med; 2012 Jan; 18(1):1-5. PubMed ID: 22139745
[TBL] [Abstract][Full Text] [Related]
18. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
19. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
